Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) Operating Expenses (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Operating Expenses for 6 consecutive years, with $77.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 22.04% to $77.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $300.1 million, a 28.4% increase, with the full-year FY2025 number at $300.1 million, up 28.4% from a year prior.
  • Operating Expenses was $77.4 million for Q4 2025 at PROCEPT BioRobotics, roughly flat from $77.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $77.4 million in Q4 2025 to a low of $14.9 million in Q1 2021.
  • A 5-year average of $45.1 million and a median of $44.3 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 89.8% in 2022, then increased 22.04% in 2025.
  • PROCEPT BioRobotics' Operating Expenses stood at $21.3 million in 2021, then skyrocketed by 67.32% to $35.7 million in 2022, then soared by 42.27% to $50.8 million in 2023, then grew by 24.74% to $63.4 million in 2024, then rose by 22.04% to $77.4 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Operating Expenses are $77.4 million (Q4 2025), $77.2 million (Q3 2025), and $73.9 million (Q2 2025).